FDG PET metabolic tumor volume segmentation and pathologic volume of primary human solid tumors

American Journal of Roentgenology

Volumn 202, Issue 5, 2014, Pages 1114-1119

  Sridhar, Praveen ^a   Mercier, Gustavo ^a   Tan, Josenia ^a   Truong, Minh Tam ^a   Daly, Benedict ^a   Subramaniam, Rathan M ^a,b  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Fixed threshold method; Gradient method; Metabolic tumor volume; Segmentation

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADULT; AGED; ARTICLE; COLORECTAL TUMOR; FEMALE; HEAD AND NECK TUMOR; HUMAN; IMAGE ANALYSIS; LUNG TUMOR; MAJOR CLINICAL STUDY; MALE; METABOLIC TUMOR VOLUME; MIDDLE AGED; PATHOLOGIC TUMOR VOLUME; PET SCANNER; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIOLOGICAL PARAMETERS; RETROSPECTIVE STUDY; STANDARDIZED UPTAKE VALUE; TUMOR VOLUME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; MIDDLE AGED; MULTIMODAL IMAGING; NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; TUMOR BURDEN;

EID: 84899514754     PISSN: 0361803X     EISSN: 15463141     Source Type: Journal    
DOI: 10.2214/AJR.13.11456     Document Type: Article

References (31)

1. 18F-FDG PET/CT as a predictive biomarker of outcome in patients with head-and-neck non- squamous cell carcinoma. AJR 2011; 197:976-980
2. 18F-FDG metabolic tumor volume and total glycolytic activity of oral cavity and oropharyngeal squamous cell cancer: adding value to clinical staging. J Nucl Med 2012; 53:709-715
3. Davison JM, Ozonoff A, Imsande HM, Grillone GA, Subramaniam RM. Squamous cell carcinoma of the palatine tonsils: FDG standardized uptake value ratio as a biomarker to differentiate tonsillar carcinoma from physiologic uptake. Radiology 2010; 255:578-585
4. Sacks A, Peller PJ, Surasi DS, Chatburn L, Mercier G, Subramaniam RM. Value of PET/CT in the management of primary hepatobiliary tumors. Part 2. AJR 2011; 197:[web]W260-W265
5. Dibble EH, Karantanis D, Mercier G, Peller PJ, Kachnic LA, Subramaniam RM. PET/CT of cancer patients. Part 1. Pancreatic neoplasms. AJR 2012; 199:952-967
6. 18F-fluoro-2-deoxy-D-glucose positron emission tomography and positron emission tomography/ computed tomography imaging of malignant pleural mesothelioma. J Med Imaging Radiat Oncol 2009; 53:160-169; quiz, 170
7. Ashamalla H, Rafla S, Parikh K, et al. The contribution of integrated PET/CT to the evolving definition of treatment volumes in radiation treatment planning in lung cancer. Int J Radiat Oncol Biol Phys 2005; 63:1016-1023 (Pubitemid 41505278)
8. Ciernik IF, Dizendorf E, Baumert BG, et al. Radiation treatment planning with an integrated positron emission and computer tomography (PET/CT): a feasibility study. Int J Radiat Oncol Biol Phys 2003; 57:853-863 (Pubitemid 37194314)
9. Geets X, Lee JA, Bol A, Lonneux M, Gregoire V. A gradient-based method for segmenting FDGPET images: methodology and validation. Eur J Nucl Med Mol Imaging 2007; 34:1427-1438 (Pubitemid 47312577)
10. Troost EG, Schinagl DA, Bussink J, et al. Innovations in radiotherapy planning of head and neck cancers: role of PET. J Nucl Med 2010; 51:66-76
11. Grégoire V, Haustermans K, Geets X, Roels S, Lonneux M. PET-based treatment planning in radiotherapy: a new standard? J Nucl Med 2007; 48(suppl 1):68S-77S (Pubitemid 47604944)
12. Tang SA, Huang G, Liu JJ, et al. Usefulness of (18) F-FDG PET, combined FDG-PET/CT and EUS in diagnosing primary pancreatic carcinoma: a meta-analysis. Eur J Radiol 2011; 78:142-150
13. 18F-fluorodeoxyglucose positron emission tomography in patients with esophageal carcinoma. Ann Surg Oncol 2010; 17:115-122
14. La TH, Filion EJ, Turnbull BB, et al. Metabolic tumor volume predicts for recurrence and death in head and neck cancer. Int J Radiat Oncol Biol Phys 2009; 74:1335-1341
15. Yang DH, Min JJ, Jeong YY, et al. The combined evaluation of interim contrast-enhanced computerized tomography (CT) and FDG-PET/CT predicts the clinical outcomes and may impact on the therapeutic plans in patients with aggressive non- Hodgkin's lymphoma. Ann Hematol 2009; 88:425-432
16. Murphy JD, Chisholm KM, Daly ME, et al. Correlation between metabolic tumor volume and pathologic tumor volume in squamous cell carcinoma of the oral cavity. Radiother Oncol 2011; 101:356-361
17. Werner-Wasik M, Nelson AD, Choi W, et al. What is the best way to contour lung tumors on PET scans? Multiobserver validation of a gradient- based method using a NSCLC digital PET phantom. Int J Radiat Oncol Biol Phys 2012; 82:1164-1171
18. Daisne JF, Duprez T, Weynand B, et al. Tumor volume in pharyngolaryngeal squamous cell carcinoma: comparison at CT, MR imaging, and FDG PET and validation with surgical specimen. Radiology 2004; 233:93-100 (Pubitemid 39280962)
19. Bowden P, Fisher R, Mac Manus M, et al. Measurement of lung tumor volumes using three-dimensional computer planning software. Int J Radiat Oncol Biol Phys 2002; 53:566-573 (Pubitemid 34626494)
20. Chiti A, Kirienko M, Gregoire V. Clinical use of PET-CT data for radiotherapy planning: what are we looking for? Radiother Oncol 2010; 96:277-279
21. van Baardwijk A, Bosmans G, Boersma L, et al. PET-CT-based auto-contouring in non-small-cell lung cancer correlates with pathology and reduces interobserver variability in the delineation of the primary tumor and involved nodal volumes. Int J Radiat Oncol Biol Phys 2007; 68:771-778 (Pubitemid 46818730)
22. Jackson T, Chung MK, Mercier G, Ozonoff A, Subramaniam RM. FDG PET/CT and inter observer agreement in head and neck cancer: FDG and CT measurements of the primary tumor site. Nucl Med Commun 2012; 33:305-312
23. 18FFDG PET-positive tissue for target volume definition in radiotherapy of patients with non-small cell lung cancer. J Nucl Med 2005; 46:1342-1348
24. 18F- FDG PET and CT non-small cell lung cancer tumor delineation. J Nucl Med 2011; 52:1690-1697
25. Hoetjes NJ, van Velden FH, Hoekstra OS, et al. Partial volume correction strategies for quantitative FDG PET in oncology. Eur J Nucl Med Mol Imaging 2010; 37:1679-1687
26. Soret M, Bacharach SL, Buvat I. Partial-volume effect in PET tumor imaging. J Nucl Med 2007; 48:932-945 (Pubitemid 46909922)
27. Romesser PB, Qureshi MM, Shah BA, et al. Superior prognostic utility of gross and metabolic tumor volume compared to standardized uptake value using PET/CT in head and neck squamous cell carcinoma patients treated with intensitymodulated radiotherapy. Ann Nucl Med 2012; 26:527-534
28. Burger IA, Vargas HA, Donati OF, et al. The value of (18)F-FDG PET/CT in recurrent gynecologic malignancies prior to pelvic exenteration. Gynecol Oncol 2013; 129:586-592
29. Bazan JG, Koong AC, Kapp DS, et al. Metabolic tumor volume predicts disease progression and survival in patients with squamous cell carcinoma of the anal canal. J Nucl Med 2013; 54:27-32
30. Lee SJ, Choi JY, Lee HJ, et al. Prognostic value of volume-based (18)F-fluorodeoxyglucose PET/CT parameters in patients with clinically node-negative oral tongue squamous cell carcinoma. Korean J Radiol 2012; 13:752-759
31. Shah B, Srivastava N, Hirsch AE, Mercier G, Subramaniam RM. Intra-reader reliability of FDG PET volumetric tumor parameters: effects of primary tumor size and segmentation methods. Ann Nucl Med 2012; 26:707-714